Skip to main content Skip to search Skip to main navigation

EC: New ways to conduct Notified Body-audits during COVID-19

On 8 April 2020, the Medical Device Coordination Group (MDCG) published a five-page guideline on the conduct of audits by Notified Bodies to be applied during the COVID 19 pandemic. 

Under certain circumstances, remote audits should now also be possible. The guideline will be effective immediately and will be valid for the duration of the COVID 19 pandemic according to the classification by the World Health Organisation (WHO).

The following audits for conformity assessments of medical devices are covered by the guideline:

  • Surveillance audits under the medical devices Directives,
  • Audits conducted for re-certification purposes under the medical devices Directives,
  • In cases where a manufacturer submits a change notification to a notified body that would typically require on-site audit or verification,
  • In cases where a manufacturer terminates (voluntarily or involuntarily) its contract with a notified body and enters into a contract with another notified body in respect of the conformity assessment of the same device(s).

The following temporary extraordinary measures and arrangements may be conducted as an alternative to on-site audits:

  • Postponement of on-site surveillance audits under the Directives in line with documented procedures of the notified body for force majeure.
  • On-site audits may be replaced by remote audits using the most advanced available Information and Communication Technologies as appropriate in accordance with legislation on information security and data protection.
  • Assessment of all relevant and required documents/records off-site by the notified body.
  • To take into account existing recent results from MDSAP audits (or other appropriate audits) in lieu of Directive audits, where available
  • To consider published international guidance such as those issued by the International Accreditation Forum (IAF) e.g. on how to use information and communication technologies and for alternative auditing methods in extraordinary circumstances

New approaches will be followed during the pandemic here as well. It needs to be shown to what extent modern communication technologies for conducting audits continue to be possible in the future.


Source:

EC: Guidance on temporary extraordinary measures related to medical device Notified Body audits during COVID-19 quarantine orders and travel restrictions

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB: Opportunities and Concerns in the MDR/IVDR Revision

Team-NB, the European association of medical device Notified Bodies, sees the proposed MDR and IVDR revision as an opportunity to improve efficiency, transparency and predictability in conformity assessment.
Read more
EMA: GMP Documentation for the Sterilisation of an API

EMA: GMP Documentation for the Sterilisation of an API

The EMA Q&A on the quality of medicines has been updated with a new question: “What kind of GMP documentation is required for an API manufacturer performing sterilisation of an active substance?”

Read more
EMA: Updated Q&A on OOS Batches of ATMPs

EMA: Updated Q&A on OOS Batches of ATMPs

The EMA has revised its questions and answers on the use of out-of-specification (OOS) batches of authorised cell- and tissue-based ATMPs (“Questions and answers on the use of out-of-specification batches of authorised cell/tissue-based ATMPs”, Rev. 1, 2026).
Read more
Previous
Next